Recent Updates — ABOS
Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial for sabirnetug (ACU193) in early Alzheimer’s disease failed to meet the primary endpoint of cognitive and functional decline at both 35 mg/kg and 50 mg/kg doses. The drug also missed key secondary endpoints, including Clinical Dementia Rating – Sum of Boxes, though it did show statistically significant amyloid plaque reduction. Consequently, Acumen plans to cease development of sabirnetug and implement cash conservation measures while evaluating strategic options for its remaining programs. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics targeting toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease.
Acumen Pharmaceuticals reported financial results for the third quarter ended September 30, 2026. The company held $78.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, a decrease from $110.2 million at June 30, 2026. Research and development expenses were $21.1 million for the quarter, compared to $22.0 million in the prior year period. The company expects to report topline results from its ALTITUDE-AD Phase 2 study investigating sabirnetug for early Alzheimer's disease in November 2026. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease.
Acumen Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2026, on August 12, 2026. The company held $110.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations into early 2027. Research and development expenses decreased to $27.8 million from $37.1 million in the prior year period due to lower manufacturing and clinical trial costs. The company expects to report topline results for its Phase 2 ALTITUDE-AD study of sabirnetug in late 2026 and targets an IND filing for its Enhanced Brain Delivery program lead candidate by mid-2027.
Acumen Pharmaceuticals, Inc. exercised its option under a collaboration agreement with JCR Pharmaceuticals Co. Ltd. to license and develop two enhanced brain delivery (EBD) candidates for Alzheimer’s disease treatment. The selected candidates include a bispecific antibody derived from sabirnetug and a next-generation amyloid-beta oligomer-selective antibody, ACU234. Preclinical studies in murine and non-human primate models showed antibody levels 14-40x higher in non-human primates than native antibodies at 24 hours, with favorable stability and low anemia risk. Acumen Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases.